These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 12377960)

  • 1. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
    Belli F; Testori A; Rivoltini L; Maio M; Andreola G; Sertoli MR; Gallino G; Piris A; Cattelan A; Lazzari I; Carrabba M; Scita G; Santantonio C; Pilla L; Tragni G; Lombardo C; Arienti F; Marchianò A; Queirolo P; Bertolini F; Cova A; Lamaj E; Ascani L; Camerini R; Corsi M; Cascinelli N; Lewis JJ; Srivastava P; Parmiani G
    J Clin Oncol; 2002 Oct; 20(20):4169-80. PubMed ID: 12377960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
    Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G
    Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.
    Mazzaferro V; Coppa J; Carrabba MG; Rivoltini L; Schiavo M; Regalia E; Mariani L; Camerini T; Marchianò A; Andreola S; Camerini R; Corsi M; Lewis JJ; Srivastava PK; Parmiani G
    Clin Cancer Res; 2003 Aug; 9(9):3235-45. PubMed ID: 12960108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.
    Eton O; Ross MI; East MJ; Mansfield PF; Papadopoulos N; Ellerhorst JA; Bedikian AY; Lee JE
    J Transl Med; 2010 Jan; 8():9. PubMed ID: 20109236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock proteins gp96 as immunogens in cancer patients.
    Parmiani G; De Filippo A; Pilla L; Castelli C; Rivoltini L
    Int J Hyperthermia; 2006 May; 22(3):223-7. PubMed ID: 16754342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
    Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
    J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
    Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
    Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
    Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM
    Front Immunol; 2020; 11():1147. PubMed ID: 32582212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells.
    Berger TG; Haendle I; Schrama D; Lüftl M; Bauer N; Pedersen LØ; Schuler-Thurner B; Hohenberger W; Straten Pt Pt; Schuler G; Becker JC
    Int J Cancer; 2004 Aug; 111(2):229-37. PubMed ID: 15197776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
    Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
    Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
    Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
    Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.
    Baba T; Sato-Matsushita M; Kanamoto A; Itoh A; Oyaizu N; Inoue Y; Kawakami Y; Tahara H
    J Transl Med; 2010 Sep; 8():84. PubMed ID: 20843377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
    Trepiakas R; Berntsen A; Hadrup SR; Bjørn J; Geertsen PF; Straten PT; Andersen MH; Pedersen AE; Soleimani A; Lorentzen T; Johansen JS; Svane IM
    Cytotherapy; 2010 Oct; 12(6):721-34. PubMed ID: 20429791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
    Filipazzi P; Valenti R; Huber V; Pilla L; Canese P; Iero M; Castelli C; Mariani L; Parmiani G; Rivoltini L
    J Clin Oncol; 2007 Jun; 25(18):2546-53. PubMed ID: 17577033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
    Testori A; Richards J; Whitman E; Mann GB; Lutzky J; Camacho L; Parmiani G; Tosti G; Kirkwood JM; Hoos A; Yuh L; Gupta R; Srivastava PK;
    J Clin Oncol; 2008 Feb; 26(6):955-62. PubMed ID: 18281670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
    Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
    J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
    Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
    Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.